© The Author (2005). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Scientific Commentary |
Genetics of Parkinson's disease: LRRK2 on the rise
| The first 150 words of the full text of this article appear below. |
Our view of the pathogenic mechanisms of Parkinson's disease has greatly changed over the past decade with the identification of several genes implicated in Mendelian forms of this disorder (Corti et al., 2005
; Gasser et al., 2005). Parkin, DJ-1 and PINK1 are responsible for autosomal recessive forms, usually with early onset, that are not associated with Lewy bodies. 
-Synuclein was considered to be the major gene responsible for autosomal dominant forms until late 2004, when the LRRK2 gene was identified (Paisan-Ruiz et al., 2004; Zimprich et al., 2004a). Despite their rarity, the discovery of -synuclein mutations or multiplications led to the demonstration that -synuclein is the major component of Lewy bodies, and clearly illustrated the gene dosage effect resulting from gene multiplications; duplications of the -synuclein gene are responsible for a late-onset typical Parkinson's disease (Chartier-Harlin et al., 2004;
1 INSERM U679 (former U289), 2 Département de Génétique, Cytogénétique et Embryologie, 3 Fédération de Neurologie and 4 Faculté de Médecine Pierre et Marie Curie, Groupe hospitalier Pitié-Salpêtrière, AP-HP, 47 boulevard de l'Hôpital, 75013, Paris, France
E-mail: brice@ccr.jussieu.fr
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Lesage, S. Belarbi, A. Troiano, C. Condroyer, N. Hecham, P. Pollak, E. Lohman, T. Benhassine, F. Ysmail-Dahlouk, A. Durr, et al. Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease? Neurology, November 4, 2008; 71(19): 1550 - 1552. [Full Text] [PDF]
|
|
|
|
|
|
C. Marras and A. Lang Invited Article: Changing concepts in Parkinson disease: Moving beyond the Decade of the Brain Neurology, May 20, 2008; 70(21): 1996 - 2003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Orr-Urtreger, C. Shifrin, U. Rozovski, S. Rosner, D. Bercovich, T. Gurevich, H. Yagev-More, A. Bar-Shira, and N. Giladi The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: Is there a gender effect? Neurology, October 16, 2007; 69(16): 1595 - 1602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lesage, S. Janin, E. Lohmann, A.-L. Leutenegger, L. Leclere, F. Viallet, P. Pollak, F. Durif, S. Thobois, V. Layet, et al. LRRK2 Exon 41 Mutations in Sporadic Parkinson Disease in Europeans Arch Neurol, March 1, 2007; 64(3): 425 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ishihara, L. Warren, R. Gibson, R. Amouri, S. Lesage, A. Durr, M. Tazir, Z. K. Wszolek, R. J. Uitti, W. C. Nichols, et al. Clinical Features of Parkinson Disease Patients With Homozygous Leucine-Rich Repeat Kinase 2 G2019S Mutations. Arch Neurol, September 1, 2006; 63(9): 1250 - 1254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Zabetian, H. Morino, H. Ujike, M. Yamamoto, M. Oda, H. Maruyama, Y. Izumi, R. Kaji, A. Griffith, B. C. Leis, et al. Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease Neurology, August 22, 2006; 67(4): 697 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lesage, A. Durr, M. Tazir, E. Lohmann, A.-L. Leutenegger, S. Janin, P. Pollak, A. Brice, and the French Parkinson's Disease Genetics Study Grou LRRK2 G2019S as a Cause of Parkinson's Disease in North African Arabs N. Engl. J. Med., January 26, 2006; 354(4): 422 - 423. [Full Text] [PDF]
|
|